Subscribe to our Email Alerts
Menu
Home
About Us
Company Overview
Company Values
Board of Directors
Executive Management
Corporate Directory
Products
DAYBUE® (trofinetide)
Pipeline
Pipeline
NNZ-2591
Phelan-McDermid Syndrome
Angelman Syndrome
Pitt Hopkins Syndrome
Hypoxic-ischemic encephalopathy
Prader-Willi Syndrome
Compassionate Use
Science
Science Behind Neuren's Products
Trofinetide Published Studies & Presentations
Rett Syndrome
NNZ-2591Published Studies & Presentations
Phelan-McDermid Syndrome
Pitt Hopkins Syndrome
Angelman Syndrome
Investors
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
News & Media
Media
Contact
Contact Us
Email Alerts
Investors
Home
>
Investors
>
ASX Announcements
Investor Dashboard
Share Price Information
ASX Announcements
Annual and Interim Reports
Investor Presentations
Corporate Governance
Analyst Coverage
Shareholder Services
ASX Announcements
Filter by Year:
2026
2025
2024
2023
2022
2021
2020
2019
Older
Aug 07, 2020
Appendix 2A
Aug 07, 2020
Change of Director's Interest Notice
Aug 05, 2020
Completion of Share Purchase Plan
Jul 30, 2020
Appointment of CFO & Company Secretary
Jul 27, 2020
Q2 2020 Activity Report and Cash Flow Report
Jul 14, 2020
Final share buy-back notice - Appendix 3F
Jul 14, 2020
Announcement of buy-back - Appendix 3C
Jul 14, 2020
Publications and presentations for trofinetide and NNZ-2591
Jul 13, 2020
Appendix 3G
Jul 09, 2020
Share Purchase Plan Offer Booklet
Previous
1
2
3
4
5
6
Next
